文献速递肝病

肝硬化的临床状态与竞争风险。

Clinical states of cirrhosis and competing risks.
PubMed 文献 · J Hepatol · 2017-10-27

综述总结肝硬化临床状态(代偿期、失代偿期及晚期失代偿状态)与竞争风险分析。这些状态不按固定顺序进展但对应不同死亡风险,慢加急性肝衰竭可发生于失代偿或代偿期肝硬化且与高短期死亡率相关。多状态模型需用竞争风险分析,传统Kaplan-Meier仅适用于两状态情形。

要点

  • 肝硬化临床状态包括代偿期、失代偿期及晚期失代偿状态,对应不同死亡风险。
  • 慢加急性肝衰竭可发生于失代偿或代偿期肝硬化,与高短期死亡率相关。
  • 多状态模型评估各状态结局概率时需用竞争风险分析。

核心结论

  • 肝硬化临床状态对应不同死亡风险,多状态模型描述其临床病程需采用竞争风险分析。

研究设计与样本

  • 综述,旨在总结肝硬化相关临床状态并展示多状态模型中的竞争风险分析示例;检索范围原文未报告。

主要发现

  • 肝硬化临床病程主要由门静脉高压进展、高动力循环、细菌易位和系统性炎症激活决定。
  • 不同疾病状态包括代偿期肝硬化、失代偿期肝硬化和晚期失代偿状态,与上述机制进展相关,可通过血流动力学或临床特征识别。
  • 这些疾病状态不遵循可预测的顺序,但对应不同的死亡风险。
  • 慢加急性肝衰竭可发生于失代偿期或代偿期肝硬化,且总是与高短期死亡率相关。

关键数值与推荐

  • 原文未报告具体标准或数值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical course of cirrhosis is mostly determined by the progressive increase of portal hypertension, hyperdynamic circulation, bacterial translocation and activation of systemic inflammation. Different disease states, encompassing compensated and decompensated cirrhosis and a late decompensated state, are related to the progression of these mechanisms and may be recognised by haemodynamic or clinical characteristics. While these disease states do not follow a predictable sequence, they correspond to varying mortality risk. Acute-on-chronic liver failure may occur either in decompensated or in compensated cirrhosis and is always associated with a high short-term mortality. The increasing severity of these disease states prompted the concept of clinical states of cirrhosis. A multistate approach has been considered to describe the clinical course of the disease. Such an approach requires the assessment of the probabilities of different outcomes in each state, which compete with each other to occur first and mark the transition towards a different state. This requires the use of competing risks analysis, since the traditional Kaplan-Meier analysis should only be used in two-state settings. Accounting for competing risks also has implications for prognosis and treatment efficacy research. The aim of this review is to summarise relevant clinical states and to show examples of competing risks analysis in multistate models of cirrhosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. D'Amico G, Morabito A, D'Amico M, et al. Clinical states of cirrhosis and competing risks. J Hepatol. 2017. PMID: 29111320. doi:10.1016/j.jhep.2017.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。